330 related articles for article (PubMed ID: 8912446)
1. Prostate-specific antigen: insufficient discrimination between benign prostatic hyperplasia and organ-confined prostate cancer.
Wolff JM; Boeckmann W; Borchers H; Handt S; Reineke T; Jakse G
Urol Int; 1996; 57(3):170-4. PubMed ID: 8912446
[TBL] [Abstract][Full Text] [Related]
2. Serum prostate-specific antigen discriminates weakly between men with benign prostatic hyperplasia and patients with organ-confined prostate cancer.
Sershon PD; Barry MJ; Oesterling JE
Eur Urol; 1994; 25(4):281-7. PubMed ID: 7519989
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of patients with diseases of the prostate using prostate-specific antigen density.
Wolff JM; Boeckmann W; Effert PJ; Handt S; Jakse G
Br J Urol; 1995 Jul; 76(1):41-6. PubMed ID: 7544203
[TBL] [Abstract][Full Text] [Related]
4. Cytokeratin 8/18 levels in patients with prostate cancer and benign prostatic hyperplasia.
Wolff JM; Borchers H; Brehmer B; Brauers A; Jakse G
Urol Int; 1998; 60(3):152-5. PubMed ID: 9644784
[TBL] [Abstract][Full Text] [Related]
5. [Improved discrimination between prostatic carcinoma and benign prostatic hyperplasia by determination of free prostate-specific antigen percentage].
Wolff JM; Borchers H; Boeckmann W; Habib FK; Jakse G
Urologe A; 1997 May; 36(3):255-8. PubMed ID: 9265347
[TBL] [Abstract][Full Text] [Related]
6. Prostate-specific antigen density values among patients with symptomatic prostatic enlargement in Nigeria.
Udeh EI; Nnabugwu II; Ozoemena FO; Ugwumba FO; Aderibigbe AS; Ohayi SR; Echetabu KN
World J Surg Oncol; 2016 Jun; 14(1):174. PubMed ID: 27356753
[TBL] [Abstract][Full Text] [Related]
7. Serum-to-urinary prostate-specific antigen ratio in patients with benign prostatic hyperplasia and prostate cancer.
Hillenbrand M; Bastian M; Steiner M; Zingler C; Müller M; Wolff JM; Seiter H; Schuff-Werner P
Anticancer Res; 2000; 20(6D):4995-6. PubMed ID: 11326656
[TBL] [Abstract][Full Text] [Related]
8. Postoperative PSA and PSA velocity identify presence of prostate cancer after various surgical interventions for benign prostatic hyperplasia.
Helfand BT; Anderson CB; Fought A; Kim DY; Vyas A; McVary KT
Urology; 2009 Jul; 74(1):177-83. PubMed ID: 19428074
[TBL] [Abstract][Full Text] [Related]
9. Increased discrimination between benign prostatic hyperplasia and prostate cancer through measurement of percentage free PSA.
Wolff JM; Boeckmann W; Effert PJ; Habib FK; Jakse G
Anticancer Res; 1997; 17(4B):2993-4. PubMed ID: 9329583
[TBL] [Abstract][Full Text] [Related]
10. Free and complexed prostate-specific antigen serum ratios to predict probability of primary prostate cancer and benign prostatic hyperplasia.
Marley GM; Miller MC; Kattan MW; Zhao G; Patton KP; Vessella RL; Wright GL; Schellhammer PF; Veltri RW
Urology; 1996 Dec; 48(6A Suppl):16-22. PubMed ID: 8973695
[TBL] [Abstract][Full Text] [Related]
11. Benign prostatic hyperplasia and prostate cancer differentiation via platelet to lymphocyte ratio.
Kaynar M; Yildirim ME; Gul M; Kilic O; Ceylan K; Goktas S
Cancer Biomark; 2015; 15(3):317-23. PubMed ID: 25586096
[TBL] [Abstract][Full Text] [Related]
12. [Significance and limitations of f/tPSA in differential diagnosis of prostate cancer with tPSA levels between 4 and 10 ng/ml].
Chen ZD; Wei SM; Cai SL
Zhonghua Wai Ke Za Zhi; 2004 May; 42(10):593-5. PubMed ID: 15265401
[TBL] [Abstract][Full Text] [Related]
13. Differentiation of benign prostatic hyperplasia and prostate cancer employing prostatic-specific antigen density.
Wolff JM; Scholz A; Boeckmann W; Jakse G
Eur Urol; 1994; 25(4):295-8; discussion 304. PubMed ID: 7519991
[TBL] [Abstract][Full Text] [Related]
14. Interpreting results of prostate-specific antigen testing for early detection of prostate cancer.
Meigs JB; Barry MJ; Oesterling JE; Jacobsen SJ
J Gen Intern Med; 1996 Sep; 11(9):505-12. PubMed ID: 8905498
[TBL] [Abstract][Full Text] [Related]
15. Free-to-total prostate-specific antigen serum concentrations in patients with prostate cancer and benign prostatic hyperplasia.
Wolff JM; Borchers H; Effert PJ; Habib FK; Jakse G
Br J Urol; 1996 Sep; 78(3):409-13. PubMed ID: 8881952
[TBL] [Abstract][Full Text] [Related]
16. Free and total prostate specific antigen in benign prostate hyperplasia and prostate cancer.
Naz S; Ahmad S; Ghafoor F; Butt NS; Akhtar MW
J Coll Physicians Surg Pak; 2004 Feb; 14(2):69-71. PubMed ID: 15228865
[TBL] [Abstract][Full Text] [Related]
17. Urinary prostate specific antigen: is the clinical use likely?
Pejcic T; Hadzi-Djokic J; Acimovic M; Topuzovic C; Milkovic B; Janjic A
Acta Chir Iugosl; 2005; 52(4):69-74. PubMed ID: 16673599
[TBL] [Abstract][Full Text] [Related]
18. Insulin-like growth factor I (IGF-I) and IGF-binding protein-3 in benign prostatic hyperplasia and prostate cancer.
Khosravi J; Diamandi A; Mistry J; Scorilas A
J Clin Endocrinol Metab; 2001 Feb; 86(2):694-9. PubMed ID: 11158033
[TBL] [Abstract][Full Text] [Related]
19. Comparison of the clinical value of complexed PSA and total PSA in the discrimination between benign prostatic hyperplasia and prostate cancer.
Froehner M; Hakenberg OW; Koch R; Schmidt U; Meye A; Wirth MP
Urol Int; 2006; 76(1):27-30. PubMed ID: 16401917
[TBL] [Abstract][Full Text] [Related]
20. [Serum and urine prostate-specific antigen ratio: its value in the distinction between prostate cancer and adenoma when serum prostate-specific antigen level is between 4 and 10 ng/ml].
Irani J; Millet C; Levillain P; Doré B; Bégon F; Aubert J
Chirurgie; 1997; 122(8-9):478-82. PubMed ID: 9616891
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]